Avivagen : Announces Attendance At AlphaNorth Capital Conference January 16 & 17, 2016

Ottawa, ON / TNW-Accesswire / Jan 15 2016 / - Avivagen Inc. (TSXV: VIV), a life sciences company commercializing products intended to eliminate the need for preventative or growth promoting antibiotics in livestock feeds and otherwise support human and animal health, announces its attendance at the AlphaNorth Capital Conference on January 16th and 17th, 2016.

This investor conference has been created by AlphaNorth Asset Management (AlphaNorth), a Toronto-based investment manager that believes superior long-term equity returns are achievable by exploiting inefficiencies in the Canadian small cap universe through careful equity selection. Further information about AlphaNorth is available at www.alphanorthasset.com.

Attendance at the investor conference is by invitation and it is intended to feature some of the best small capitalization innovators in the technology, biotech, healthcare and special situations spaces and connect them with the top institutions and specialist brokers in North America. The conference takes place at the Atlantis Resort on Paradise Island in the Bahamas, with further information available at www.capitaleventmanagement.ca/events.html.

Avivagen's CEO, Cameron Groome, is scheduled for a day of 18 meetings on Saturday, January 16th, 2016. The meetings will start at 9:00 AM Eastern Time (UTC-05:00) and each meeting will be of 20 minutes duration. The corporate PowerPoint presentation to which Mr. Groome will be speaking will be posted to the Avivagen website on Friday, January 15th, 2016.

Attendance at such investor conferences provides a forum to communicate with current and prospective shareholders. Effective shareholder communications can help to optimize the trading liquidity of Avivagen shares and to ensure their efficient valuation by capital markets.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol 'VIV' and on OTC Pink as 'CHEXF.' The Company's goal is to develop and deliver scientifically-proven products that benefit human and animal health. Its target markets include livestock health and productivity, companion animal quality-of-life and maintaining optimal health in humans.

Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.
About Avivagen's Technology
Avivagen has a proprietary and patented technology from its discoveries about carotenoid oxidation. The food-borne oxidation compounds discovered by Avivagen help the body's own systems to maintain and enhance health, by supporting immune function against bacteria and calming excess inflammation. Avivagen's commercial-stage application of its inventions is fully-oxidized beta-carotene, OxC-beta™ Technology (OxC-beta). OxC-beta occurs naturally as carotenoid oxidation products in vegetation, but in minute amounts. Avivagen is developing OxC-beta as a replacement for the use of antibiotics for disease prevention and growth promotion in livestock feeds, to enhance the quality of life of companion animals and to help maintain optimal health in humans. Avivagen's commercial products are OxC-beta™ Livestock (Kingdom of Thailand), Vivamune™ Vital Health3 Chews (U.S.) and Oximunol™ Chewable Tablets (U.S.).

Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions 'aim', 'anticipate', 'appear', 'believe', 'consider', 'could', 'estimate', 'expect', 'if', 'intend', 'goal', 'hope', 'likely', 'may', 'plan', 'possibly', 'potentially', 'seem', 'should', 'whether', 'will', 'would' and similar expressions. Statements about uses of the technologies described in this news release, including their importance to animal or human health, their novelty, safety, efficacy or affordability, or about AlphaNorth, the AlphaNorth conference or the intentions, relevance or outcomes of the conference, are all forward looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Such Avivagen risks and uncertainties include, but are not limited to, the following: its ability to continue as a going concern; the results of ongoing or future trials may not be positive or sufficiently positive; even if the results of trials are positive, there is no guarantee that its products will be commercially successful or that requisite regulatory approvals will be obtained; the timing and results of trials may be delayed or may not be completed at all; and intellectual property rights may prove inadequate to protect its inventions. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc.
Cameron Groome, CEO & President
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: [phone]
Website: www.avivagen.com
Copyright © 2016 Avivagen Inc.
OxC-beta™, Vivamune™ and Oximunol™ are trademarks of Avivagen Inc.